Revance Therapeutics (RVNC) Misses Q4 EPS by $1.08

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($1.82), $1.08 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $44.91 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Old Dominion Freight Line (ODFL) Reiterated at Buy by Stifel Amid Seasonally Softer Q4/Q1
• Change in Nonfarm Payrolls (Aug) 162K vs 55K Expected, Unemployment Rate 4.1%